Mp26-17 Risk of Nephrolithiasis in Long-Term Topiramate and Zonisamide Users

You have accessJournal of UrologyStone Disease: Medical Medicare: HR, 1.22 95% CI, 1.11-1.34). A dose-response relationship was observed such that the hazard of a symptomatic stone event increased with higher medication dosages. CONCLUSIONS: Patients on TZ have a higher risk of symptomatic kidney stones than their age- and sex- matched controls. Therefore, clinicians who prescribe TZ should be fully transparent about this risk when they counsel patients. Download PPT Source of Funding: The National Institute of Diabetes and Digestive and Kidney Diseases © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e420 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Bassel S. Salka More articles by this author Mary K. Oerline More articles by this author Phyllis Yan More articles by this author Ryan S. Hsi More articles by this author Joseph J. Crivelli More articles by this author John R. Asplin More articles by this author Vahakn B. Shahinian More articles by this author John M. Hollingsworth More articles by this author Expand All Advertisement PDF downloadLoading ...